Mouse, pig and human placental aging linked to macrophage CD38 depleting NAD⁺
In aged placentas from humans, mice and pigs, the abstract reports more macrophage CD38 and less NAD⁺; in experiments, macrophage CD38 depleted NAD⁺ in decidual stromal cells and promoted placental senescence. [1]
Automatic summary · not editorially reviewed
The key findings
Aged placentas in humans, mice and pigs shared increased macrophage CD38 expression and NAD⁺ deficiency. [1]
In experiments, macrophage CD38 depleted NAD⁺ in decidual stromal cells and promoted placental senescence. [1]
NAD⁺ precursors or CD38 inhibitors attenuated age-related placental senescence and rescued intrauterine growth restriction in the reported work. [1]
The source at a glance
- Study type / format
- Abstract of a preclinical and multi-species laboratory study
- Population / context
- Placentas from humans, mice and pigs, plus decidual stromal cells and macrophages in experiments.
- Summary based on
- Study abstract
- Original publication
- August 27, 2026
Aged placentas in three species show CD38 and NAD⁺ changes
The abstract describes delayed childbearing as increasingly common and calls age-related placental senescence important to understand. Combining metabolomics, single-cell RNA sequencing and spatial transcriptomics, the authors report conserved features of aged placentas in humans, mice and pigs: increased CD38 expression in macrophages and NAD⁺ deficiency. These are described as features of aged placentas, not as causes of aging itself.
Supporting source [1]
Macrophage CD38 depletes stromal-cell NAD⁺ in experiments
Using pharmacological and genetic approaches, the authors report that macrophage CD38 depletes NAD⁺ in decidual stromal cells, thereby promoting placental senescence. They further describe early-onset inflammation and senescence-associated secretory phenotype activity driving CD38 expression in macrophages via the IRF5 pathway. These mechanistic statements come from the abstract; the underlying experiments are not detailed there.
Supporting source [1]
NAD⁺ precursors and CD38 inhibitors in the abstract
The abstract states that treatment with NAD⁺ precursors or CD38 inhibitors attenuated age-related placental senescence, rescued intrauterine growth restriction and improved long-term metabolic outcomes in offspring. It presents CD38 as a potential therapeutic target for age-associated pregnancy complications. These are reported findings and a proposed target, not an established treatment for people; the abstract gives no doses, human trial data or safety results.
Supporting source [1]
How to interpret this
This is an abstract; the full text was not reviewed. It reports no sample sizes, follow-up durations, effect sizes or human trial data, and the treatment results are preclinical findings, not established human benefits.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Hua L, Yang X, Gao D, Yang X, Jin X, Ma L, Liu W, Li J, Shen Z, Liu L, Wu Y, Yang Y, Zhu C, Li L, Jiang X, Han X, Jin C, Liu G, Feng B, Che L, Xu S, Lin Y, Fang Z, Jin L, Luo T, Zhuo Y, Li M, Wu. · europepmc.org · August 27, 2026